Cathelicidins as immunomodulators of host defence against infectious diseases
Cathelicidins 作为宿主防御传染病的免疫调节剂
基本信息
- 批准号:G1002046/1
- 负责人:
- 金额:$ 241.41万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Fellowship
- 财政年份:2011
- 资助国家:英国
- 起止时间:2011 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Lung diseases are among the most common causes of ill-heath, accounting for 20% of deaths in the UK, with one third due to infectious diseases. The rise of superbugs is a ever increasing challenge, urgently requiring new treatments and a greater understanding of the body‘s natural protective mechanisms.Important components of our body‘s early defence system are cationic host-defence peptides (CHDP). Initially studied for their ability to kill bacteria and viruses, we have discovered many ways in which CHDP can alter inflammation, modulating the body‘s response to threat and damage, and the repair systems. CHDP are therefore drug templates with the capacity to kill microbes and enhance our natural protective responses. CHDP also offer the potential to circumvent the strategies that make superbugs resistant to our current conventional treatments.Building upon the foundation I have established with my recent research, I propose to: 1) determine the cellular pathways involved in the key activities of CHDP (particularly regulating the responses of airway lining cells to infection), 2) determine the role of these activities in protecting against the establishment of infection, and 3) design novel CHDP as potential therapeutics, with a particular focus on the treatment of pathogenic lung viruses, including influenza.
肺部疾病是最常见的疾病原因之一,占英国死亡人数的20%,其中三分之一是由于传染病。超级细菌的崛起是一个日益严峻的挑战,迫切需要新的治疗方法和对人体自然保护机制的更深入了解。我们身体早期防御系统的重要组成部分是阳离子宿主防御肽(CHDP)。最初研究它们杀死细菌和病毒的能力,我们已经发现了CHDP可以改变炎症的许多方式,调节身体对威胁和损伤的反应以及修复系统。因此,CHDP是具有杀死微生物和增强我们自然保护反应能力的药物模板。CHDP还提供了潜在的规避策略,使超级细菌对我们目前的常规治疗产生抗药性。在我最近的研究建立的基础上,我建议:1)确定参与CHDP关键活性的细胞途径(特别是调节气道衬里细胞对感染的反应),2)确定这些活性在防止感染建立中的作用,和3)设计新的CHDP作为潜在的治疗剂,特别关注治疗致病性肺病毒,包括流感。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Donald Davidson其他文献
A mobile knowledge management and decision support tool for soil analysis
- DOI:
10.1016/j.ijinfomgt.2009.02.004 - 发表时间:
2009-10-01 - 期刊:
- 影响因子:
- 作者:
Julie Cowie;David Cairns;Martin Blunn;Clare Wilson;Edward Pollard;Donald Davidson - 通讯作者:
Donald Davidson
On saying that
- DOI:
10.1007/bf00568054 - 发表时间:
1968-12-01 - 期刊:
- 影响因子:1.300
- 作者:
Donald Davidson - 通讯作者:
Donald Davidson
Kant’s Theoretical Philosophy: The ‘Analytic’ Tradition
康德的理论哲学:“分析”传统
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
James R. O’Shea;S. Baiasu;eds Mark Timmons;Wilfrid S. Sellars;Gareth Evans;Hilary Putnam;Donald Davidson;Michael Dummett;John McDowell;Rae Langton;R. Brandom - 通讯作者:
R. Brandom
Clinical Evaluation of a Universal Dentin Bonding Resin: Preserving Dentition Through New Materials
- DOI:
10.14219/jada.archive.1993.0229 - 发表时间:
1993-11-01 - 期刊:
- 影响因子:
- 作者:
Ronald Jordan;Makoto Suzuki;Donald Davidson - 通讯作者:
Donald Davidson
Quotation
- DOI:
10.1007/bf00126690 - 发表时间:
1979-03-01 - 期刊:
- 影响因子:0.600
- 作者:
Donald Davidson - 通讯作者:
Donald Davidson
Donald Davidson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Donald Davidson', 18)}}的其他基金
SBIR Phase II: Stress Pathway Inhibition To Prevent COVID-19 Infection (COVID-19)
SBIR 第二阶段:通过抑制应激途径预防 COVID-19 感染 (COVID-19)
- 批准号:
2150149 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别:
Cooperative Agreement
SBIR Phase I: Stress Pathway Inhibition Prevents COVID-19 Infection (COVID-19)
SBIR 第一阶段:应激途径抑制可预防 COVID-19 感染 (COVID-19)
- 批准号:
2035793 - 财政年份:2021
- 资助金额:
$ 241.41万 - 项目类别:
Standard Grant
相似海外基金
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations
上呼吸道病毒感染引起的哮喘加重中的鼻肺交互作用
- 批准号:
10733754 - 财政年份:2023
- 资助金额:
$ 241.41万 - 项目类别:
Project 2: The New Era of Cellular Therapies For Lung Transplant Tolerance
项目 2:肺移植耐受细胞疗法的新时代
- 批准号:
10622128 - 财政年份:2023
- 资助金额:
$ 241.41万 - 项目类别:
The role of translation initiation factor eIF5B in lung cancer pathogenesis
翻译起始因子eIF5B在肺癌发病机制中的作用
- 批准号:
10734752 - 财政年份:2023
- 资助金额:
$ 241.41万 - 项目类别:
Novel Strategies to Clear Bacteria from the CF Lung
清除 CF 肺细菌的新策略
- 批准号:
10544476 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别:
Novel Strategies to Clear Bacteria from the CF Lung
清除 CF 肺细菌的新策略
- 批准号:
10680454 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别:
Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia
类卵泡抑素 1 介导细菌性肺炎中的宿主防御
- 批准号:
10636904 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别:
Subtyping sepsis in Uganda using clinical, pathogen, and host response profiling
使用临床、病原体和宿主反应分析对乌干达脓毒症进行分型
- 批准号:
10448162 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别:
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway
在口腔和上呼吸道启动针对 SARS COV2 的免疫反应
- 批准号:
10446223 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别:
PLURIPOTENCY OF NOVEL TICK CYSTEINE PROTEASE INHIBITORS DURING HEMATOPHAGY
新型蜱半胱氨酸蛋白酶抑制剂在吸血过程中的多能性
- 批准号:
10515240 - 财政年份:2022
- 资助金额:
$ 241.41万 - 项目类别: